Financial Snapshot

Revenue
$3.314M
TTM
Gross Margin
48.64%
TTM
Net Earnings
-$10.42M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
114.09%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$5.949M
Q3 2024
Cash
Q3 2024
P/E
-0.6990
Nov 29, 2024 EST
Free Cash Flow
-$2.949M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2024 2023 2022 2021 2020 2019 2018 2017
Revenue $3.112M $1.257M $437.1K $1.980M $188.7K $0.00 $0.00 $0.00
YoY Change 147.58% 187.52% -77.93% 949.32%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2024 2023 2022 2021 2020 2019 2018 2017
Revenue $3.112M $1.257M $437.1K $1.980M $188.7K $0.00 $0.00 $0.00
Cost Of Revenue $1.686M $930.2K
Gross Profit $1.426M $326.7K
Gross Profit Margin 45.81% 25.99%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2024 2023 2022 2021 2020 2019 2018 2017
Selling, General & Admin $9.259M $8.030M $4.920M $3.359M $2.203M $2.650M $2.080M $170.0K
YoY Change 15.3% 63.21% 46.47% 52.47% -16.86% 27.4% 1123.53%
% of Gross Profit 649.43% 2458.15%
Research & Development $1.674M $510.0K $3.854M $3.836M $588.2K $3.180M $2.530M
YoY Change 228.2% -86.77% 0.48% 552.1% -81.5% 25.69%
% of Gross Profit 117.41% 156.12%
Depreciation & Amortization $974.4K $814.5K $0.00
YoY Change 19.63%
% of Gross Profit 68.35% 249.33%
Operating Expenses $12.13M $13.66M $8.774M $7.195M $2.791M $5.830M $4.610M $170.0K
YoY Change -11.17% 55.68% 21.95% 157.75% -52.12% 26.46% 2611.76%
Operating Profit -$10.28M -$12.60M -$8.337M -$5.573M
YoY Change -18.36% 51.08% 49.58%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2024 2023 2022 2021 2020 2019 2018 2017
Interest Expense $92.24K $1.930M $2.900K -$1.487M -$336.0K -$660.0K -$450.0K -$140.0K
YoY Change -95.22% 66451.72% -100.2% 342.53% -49.1% 46.67% 221.43%
% of Operating Profit
Other Income/Expense, Net $92.24K $1.931M $2.900K -$1.487M
YoY Change -95.22% 66475.1% -100.2%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2024 2023 2022 2021 2020 2019 2018 2017
Pretax Income -$10.19M -$10.66M -$8.334M -$7.060M -$3.193M -$7.390M -$5.060M -$310.0K
YoY Change -4.4% 27.91% 18.04% 121.12% -56.79% 46.05% 1532.26%
Income Tax
% Of Pretax Income
Net Earnings -$10.16M -$10.63M -$8.306M -$7.037M -$3.164M -$7.340M -$5.020M -$310.0K
YoY Change -4.47% 28.0% 18.03% 122.43% -56.9% 46.22% 1519.35%
Net Earnings / Revenue -326.4% -845.89% -1900.06% -355.33% -1676.26%
Basic Earnings Per Share -$6.38 -$10.58 -$0.57 -$0.68
Diluted Earnings Per Share -$6.38 -$10.58 -$566.4K -$675.7K -$371.8K -$875.9K -$608.5K -$37.58K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2024 2023 2022 2021 2020 2019 2018 2017
Cash & Short-Term Investments $6.304M $1.540M $8.238M $12.57M $427.3K $200.0K $420.0K $60.00K
YoY Change 309.36% -81.31% -34.48% 2842.8% 113.64% -52.38% 600.0%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $474.3K $510.0K $163.1K $2.424M $1.893M $2.030M $2.050M $610.0K
YoY Change -7.01% 212.63% -93.27% 28.05% -6.74% -0.98% 236.07%
Inventory $777.5K $980.0K
Prepaid Expenses
Receivables $429.7K $290.0K
Other Receivables $548.7K $540.0K
Total Short-Term Assets $8.534M $3.860M $10.87M $18.21M $2.340M $2.330M $2.500M $670.0K
YoY Change 121.09% -64.48% -40.31% 678.1% 0.43% -6.8% 273.13%
Property, Plant & Equipment $872.6K $1.240M $391.4K
YoY Change -29.63% 216.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $135.7K
YoY Change -100.0%
Other Assets $0.00 $504.0K $0.00
YoY Change -100.0%
Total Long-Term Assets $5.245M $6.490M $1.484M $3.652M $135.7K $0.00 $0.00 $0.00
YoY Change -19.19% 337.28% -59.36% 2591.67%
Total Assets $13.78M $10.35M $12.35M $21.86M $2.476M $2.330M $2.500M $670.0K
YoY Change
Accounts Payable $602.3K $1.200M $715.9K $1.356M $483.6K $900.0K $170.0K $340.0K
YoY Change -49.81% 67.62% -47.2% 180.39% -46.27% 429.41% -50.0%
Accrued Expenses $1.351M $1.360M $1.111M $125.4K $1.826M $240.0K $90.00K
YoY Change -0.63% 22.47% 785.58% -93.13% 660.91% 166.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $5.134M $5.130M $4.840M $3.530M
YoY Change -100.0% 0.07% 5.99% 37.11%
Long-Term Debt Due $515.3K $350.0K
YoY Change 47.22%
Total Short-Term Liabilities $5.451M $5.880M $4.663M $3.683M $7.690M $6.310M $5.560M $6.580M
YoY Change -7.3% 26.1% 26.62% -52.11% 21.88% 13.49% -15.5%
Long-Term Debt $0.00 $400.0K $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $144.9K $380.0K $1.143M $3.170M $0.00
YoY Change -61.86% -66.77% -63.93%
Total Long-Term Liabilities $144.9K $780.0K $1.143M $3.170M $0.00 $0.00 $0.00 $0.00
YoY Change -81.42% -31.78% -63.93%
Total Liabilities $5.450M $6.560M $5.727M $6.802M $7.662M $6.940M $6.870M $6.580M
YoY Change -16.93% 14.54% -15.79% -11.23% 10.41% 1.02% 4.41%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2024 2023 2022 2021 2020 2019 2018 2017
Basic Shares Outstanding 1.593M shares 1.005M shares 14.67M shares 10.41M shares
Diluted Shares Outstanding 1.593M shares 1.005M shares 733.3K shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $7.2821 Million

About INTELLIGENT BIO SOLUTIONS INC.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2020-12-23. Its segment includes Commercially available Intelligent Fingerprinting Products and Development Stage Biosensor Platform Technology. Its product portfolio includes Intelligent Fingerprinting Platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader, and a two-part system that consists of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The Biosensor Platform is designed to detect multiple biological analytes by substituting the top enzyme layer of the biosensor to suit each analyte and to develop a range of Point of Care Tests, including the modalities of clinical chemistry, immunology, tumor markers, allergens, and endocrinology.

Industry: Surgical & Medical Instruments & Apparatus Peers: ABBOTT LABORATORIES ALLIED HEALTHCARE PRODUCTS INC MICRON SOLUTIONS INC /DE/ ThermoGenesis Holdings, Inc. Nuwellis, Inc. INVIVO THERAPEUTICS HOLDINGS CORP. Motus GI Holdings, Inc. ENCISION INC ReShape Lifesciences Inc.